Antidiabetic Rosiglitazone Reduces Soluble Intercellular Adhesion Molecule-1 Level in Type 2 Diabetic Patients with Coronary Artery Disease
Figure 1
(a) Changes in levels of hemoglobin A1c, (b) fasting plasma insulin, and
(c) glucose, as well as (d) HOMA-IR, with 6-month rosiglitazone
treatment. Data are means
± SD. Control group, ; rosiglitazone (RSG) group, . HbA1c: hemoglobin A1c;
HOMA-IR: homeostasis
model assessment-insulin resistance.